October 9, 2025Scientific ReportsOpen Access

TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype

View Full Paper

Ask AI

Bookmark

Individuals with the TP53 p.R181H variant show lower cancer incidence and better survival than other variants.
The variant is identified in 22% of families in the Swedish cohort, significantly higher than just 0.6% in the NCI database.
Female carriers tend to develop breast cancer, while male carriers primarily develop prostate cancer, showcasing distinct phenotype characteristics.
Potential implications suggest tailored surveillance strategies could focus testing on adults and prioritize certain cancer types.

Discussion

No takes yet. Share an insight, caveat, or question.

Analysis reveals TP53 p.R181H variant associates with lower cancer incidence in Swedish individuals, suggesting tailored approaches for surveillance.

Sun-Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals TP53 p.R181H variant associates with lower cancer incidence in Swedish individuals, suggesting tailored approaches for surveillance.